Metabolic Syndrome and Heart Failure Dynamics

Metabolic syndrome denotes a constellation of interrelated metabolic derangements—including central obesity, insulin resistance, dyslipidaemia and hypertension—that collectively accelerate atherosclerosis, myocardial remodelling and end‐organ dysfunction. In heart failure, these perturbations influence both systolic and diastolic performance by promoting lipotoxicity, inflammation, endothelial dysfunction and neurohormonal activation. The resultant spectrum of myocardial impairment ranges from subtle alterations in myocardial strain to manifest reductions in ejection fraction or elevated filling pressures. Moreover, metabolic syndrome predisposes to distinct heart failure phenotypes, notably heart failure with preserved ejection fraction, in which diastolic stiffness and ventricular–arterial uncoupling predominate. Understanding the bidirectional interplay between metabolic dysregulation and cardiac dynamics is critical for risk stratification and for the development of targeted therapies that address both metabolic and haemodynamic pathways.

Research from Nature Portfolio

Recent work has demonstrated that elevated circulating triglyceride concentrations are independently associated with increased left ventricular mass in patients with untreated hypertension, even after adjustment for traditional risk factors. This study revealed a gender‐specific effect, with men exhibiting a stronger relationship between triglyceride levels and left ventricular hypertrophy than women. The findings underscore triglycerides as a potential marker for early myocardial remodelling and a target for risk stratification in hypertensive populations.

Metabolic Syndrome and Heart Failure Dynamics publication trend

The graph below shows the total number of articles in metabolic syndrome and heart failure dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolic syndrome: A clustering of central obesity, insulin resistance, dyslipidaemia and hypertension that elevates cardiovascular risk.

Left ventricular mass index (LVMI): A normalised measure of myocardial mass, indexed to body surface area, reflecting hypertrophy.

Global longitudinal strain (GLS): A quantitative echocardiographic parameter assessing myocardial deformation along the long axis, sensitive to early systolic dysfunction.

Allostatic load: A composite index of cumulative physiological wear and tear arising from chronic stress, encompassing hormonal and metabolic biomarkers.

Heart failure with preserved ejection fraction (HFpEF): A phenotype of heart failure characterised by normal or near-normal ejection fraction but impaired ventricular compliance and diastolic filling.

Speckle tracking echocardiography: An imaging technique that tracks natural acoustic markers in the myocardium to quantify strain and detect subclinical dysfunction.

References

1. Triglycerides are related to left ventricular mass in hypertensive patients independently of other cardiometabolic risk factors: the effect of gender. Scientific Reports (2020).
2. The additive effect of metabolic syndrome on left ventricular impairment in patients with obstructive coronary artery disease assessed by 3.0 T cardiac magnetic resonance feature tracking. Cardiovascular Diabetology (2024).
3. The association between metabolic syndrome and heart failure in middle-aged men and women : population-based study of 2 million individuals. Epidemiology and Health (2022).
4. Association between allostatic load and adverse outcomes among older patients with heart failure with preserved ejection fraction. BMC Geriatrics (2023).